<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Recent studies in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> patients and Trastuzumab therapy (Herceptin) showed a development of a toxic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> as a severe complication </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to discover early changes in cardiac function and <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We studied 42 female patients with Her-2/-neu over-expression in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> by echocardiography before, 3, and 6 months after start of the adjuvant Herceptin therapy </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> values were mean value ± standard deviation </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After 3 or 6 months of a trastuzumab therapy we discovered significant increases in the diastolic and systolic left ventricle volume indices (LV-DVI 32.4 ± 8.5 vs. 38.5 ± 8.7 vs. 40.3 ± 10.3 ml/m², p &lt; 0.001 and LV-SVI 12.6 ± 4.0 vs. 15.7 ± 4.7 vs. 17.2 ± 6.8 ml/m², p &lt; 0.001), an increase of the end-diastolic and end-systolic LV diameter (LVEDD 46.8 ± 4.2 vs. 48.0 ± 4.7 vs. 49.7 ± 4.5 ml/m², p &lt; 0.01; LVESD 28.3 ± 4.2 vs. 31.0 ± 4.7 vs. 32.3 ± 4.9 mm, p &lt; 0.001), a reduced systolic ventricle function determined by the tissue Doppler imaging (<z:chebi fb="0" ids="53555">TDI</z:chebi>) velocity (9.2 ± 2.5 vs. 8.0 ± 1,7 vs. 7.7 ± 1.5 cm/s, p &lt; 0.001), fractional shortening (39,6 ± 7.5 vs. 35.4 ± 7.4 vs. 35.2 ± 7.0%, p &lt; 0.01), and the LV-EF Simpson biplane [62.0 ± 5.1 vs. 60.1 ± 6.3 (p = ns) vs. 58.4 ± 7.9%, p &lt; 0.01] compared to pretreatment values </plain></SENT>
<SENT sid="5" pm="."><plain>There was also an increase of the left atrial volume index (21.4 ± 6.2 vs. 26.2 ± 7.9 vs. 29.7 ± 8.8 ml/m², p &lt; 0.001), a decrease of the median <z:chebi fb="0" ids="53555">TDI</z:chebi> atrial velocities (11.9 ± 2.4 vs. 10.5 ± 2.8 vs. 10.1 ± 2.1 cm/s, p &lt; 0.01), an increase of the peak early diastolic filling velocities (73.1 ± 15.4 vs. 83.1 ± 16.4 vs. 82.2 ± 19.4 cm/s, p &lt; 0.05), and an increase of the median <z:hpo ids='HP_0001653'>mitral valve insufficiency</z:hpo> degree (0.64 ± 0.65 vs. 1.03 ± 0.76 vs. 1.11 ± 0.73°, p &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>We could not detect a significant increase in diastolic dysfunction </plain></SENT>
<SENT sid="7" pm="."><plain>Also right heart diameters and function did not change significantly </plain></SENT>
<SENT sid="8" pm="."><plain>Most patients stayed in an asymptomatic stage of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The blockade of Her2/-neu receptors with trastuzumab in patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> led to measurable alterations of left ventricular volume, left atrial volume, and systolic function as early as 3 months after start of treatment </plain></SENT>
</text></document>